Trump’s move to transform US pharma manufacturing raises doubts over its effectiveness: GlobalData Read more
China’s biopharma commands $30 billion in oncology licensing deals, triples US output in 2024 Read more
Donald Trump’s return sparks uncertainty for US pharma and healthcare industries: GlobalData Read more